Discover and develop innovative respiratory medicines. Commercialize YUPELRI for chronic obstructive pulmonary disease (COPD). Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 8.3× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 68% of them.
Analysts' average target sits 0% below today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 99% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 18% a year on average.
There is $315.4M in the vault; even if every debt were paid off, $239.9M would remain.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, TBPH sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TBPH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.